Cytokinetics (CYTK) Misses Q3 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $62.31 --0%
EPS Growth %: +43.1%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +43.1%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.52), $0.35 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $2.52 million versus the consensus estimate of $3.16 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- Flutter Entertainment plc (FLUT) Misses Q3 EPS by 525c; lowers guidance
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
